EASL clinical practice guidelines recommendations for drug-induced liver injury in 2019
10.3760/cma.j.issn.1007-3418.2019.06.006
- VernacularTitle: 2019年欧洲肝脏研究协会临床实践指南：药物性肝损伤的推荐意见
- Author:
Liwei LIU
1
;
Xinyan ZHAO
;
Jidong JIA
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China
- Publication Type:Journal Article
- Keywords:
Guideline;
Diagnosis;
Therapy;
Drug-induced liver injury
- From:
Chinese Journal of Hepatology
2019;27(6):420-423
- CountryChina
- Language:Chinese
-
Abstract:
Idiosyncratic (unpredictable) drug-induced liver injury (iDILI) is one of the most challenging liver diseases encountered by hepatologists due to its diverse clinical and pathological manifestations and lack of specific diagnostic markers. An increasing awareness of iDILI diagnosis and carefully excluding liver damage induced by other causes is the key to a proper diagnosis of iDILI. However, delayed diagnosis, inappropriate monitor and care leads to serious clinical consequences, such as acute liver failure or even liver-related death. In addition, there is presently no effective treatment for iDILI. Herein, we presented the main recommendations of the recent EASL published first DILI guidelines into Chinese language to facilitate liver disease authors and health workers to understand the latest research progress of DILI.
